"Vaccinogen is the first company to have developed an approach that uses the patient's own colon cancer tumor cells to 'train' the body's immune system to attack residual cancer cells and prevent recurrence of this disease which is plagued by genetic mutations that make one-size-fits-all therapies ineffective or toxic for most patients," Dr. Vermorken said. "I believe that Vaccinogen's unique processes, which include proprietary cell sterilization techniques, have the potential to fundamentally change the way we treat cancer. I'm honored to have not only worked directly with this therapy for much of my career but also to now become a part of the medical advisory board."
Dr. Vermorken was the principal investigator of the first Phase III clinical trial for OncoVAX in the treatment of colon cancer.
Dr. Vermorken's main research areas include early clinical and pharmacological studies with new drugs; studies on the interaction of chemotherapy and radiation therapy; research into the links between human papillomavirus (HPV) and various malignancies; and clinical investigation of new immunological approaches. He is Emeritus Professor of Oncology at the University of Antwerp and past head of the department of oncology at the Antwerp University Hospital. In March 2013, he was awa
|SOURCE Vaccinogen, Inc.|
Copyright©2012 PR Newswire.
All rights reserved